Alx Oncology Holdings Inc
Research Alx Oncology Holdings Inc (ALXO) on Bullrun: market cap USD 276.43M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALXO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 276.43M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.97M
- Free cash flow-USD 16.07M
Valuation Snapshot
latest market cap is USD 276.43M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 101.70M | -USD 84.35M | n/a | -1.9 | USD 16.37M | USD 9.75M | USD 25.98M |
| FY2024 | USD 0 | -USD 134.85M | -USD 122.36M | n/a | -2.58 | USD 17.57M | USD 9.90M | USD 113.62M |
| FY2023 | n/a | -USD 160.81M | -USD 131.64M | n/a | -3.74 | USD 22.41M | USD 9.64M | USD 189.71M |
| FY2022 | USD 0 | -USD 123.48M | -USD 90.65M | n/a | -3.03 | USD 48.82M | USD 9.39M | USD 263.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 276.43M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 61.46M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 88.60M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 741.80M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 459.31M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 872.22M | n/a | n/a | n/a |
About Alx Oncology Holdings Inc
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alx Oncology Holdings Inc's market cap?
Alx Oncology Holdings Inc's market capitalization is USD 276.43M.
What does Alx Oncology Holdings Inc do?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.